The Anti-Osteoanabolic Function of Sclerostin Is Blunted in Mice Carrying a High Bone Mass Mutation of Lrp5.
about
Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and ChallengesMutations in Known Monogenic High Bone Mass Loci Only Explain a Small Proportion of High Bone Mass CasesThe Lrp4R1170Q Homozygous Knock-In Mouse Recapitulates the Bone Phenotype of Sclerosteosis in Humans.Efficacy of anti-sclerostin monoclonal antibody BPS804 in adult patients with hypophosphatasia.[Regulation of bone metabolism in osteoporosis : novel drugs for osteoporosis in development].Osteocytic oxygen sensing controls bone mass through epigenetic regulation of sclerostin.
P2860
The Anti-Osteoanabolic Function of Sclerostin Is Blunted in Mice Carrying a High Bone Mass Mutation of Lrp5.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
The Anti-Osteoanabolic Functio ...... gh Bone Mass Mutation of Lrp5.
@en
type
label
The Anti-Osteoanabolic Functio ...... gh Bone Mass Mutation of Lrp5.
@en
prefLabel
The Anti-Osteoanabolic Functio ...... gh Bone Mass Mutation of Lrp5.
@en
P2093
P2860
P356
P1476
The Anti-Osteoanabolic Functio ...... gh Bone Mass Mutation of Lrp5.
@en
P2093
Anke Jeschke
Franz Jakob
Michael Amling
Peggy Benisch
Stephanie Peters
Thorsten Schinke
Timur A Yorgan
P2860
P304
P356
10.1002/JBMR.2461
P577
2015-06-08T00:00:00Z